The University of Southampton
University of Southampton Institutional Repository

Antiviral mechanisms in varicella-zoster virus infections

Antiviral mechanisms in varicella-zoster virus infections
Antiviral mechanisms in varicella-zoster virus infections

Six varicella-zoster virus (VZV)-infected cell surface proteins, M{}r 170K, 105K, 93K, 81K, 53K and 45K, were identified following extrinsic radiolabelling of the cell surface, immunoprecipitation of detergent-solubilized extract of the same cell surface and fractionation of the immunoprecipitates using SDS-PAGE. All six were shown to be glycosylated by their affinity for Ricin communis agglutinin 1 lectin. The glycoprotein with M{}r 170K in non-reduced PAGE was shown to be a disulphide bond-linked protein as under reducing conditions it was cleaved to a subunit, M{}r 63K. The human serum IgG response to these glycoproteins during various clinical circumstances was investigated. Antibodies reactive with these glycoproteins could not be detected in acute sera from the chickenpox patients and in the majority of acute shingles cases. Antibodies reactive with glycoproteins with M{}r 170K, 105K, 53K and 45K were identified in post-varicella sera, whilst during zoster convalescence antibodies to all six were prominent. Antibodies to the disulphide bond-linked glycoprotein persisted for many years following both the primary disease and its reactivation. Disseminated zoster was associated with significantly low levels of antibodies to these surface glycoproteins. Virological studies were carried out in 28 non-immunocompromised patients with herpes zoster who received treatment with the antiviral acyclovir (5 mg/kg) or placebo intravenously three times daily for five days. Mean duration of virus shedding was not significantly different in the two groups and all patients developed high titres of IgG antibodies to varicella-zoster virus, IgM and IgA responses were also detected. Interferon levels in sequential vesicle fluids reached a peak significantly sooner (p< 0.025) and at a lower level in eight treated patients compared with eight given placebo. Twenty-five VZV isolates from the zoster patients were tested for sensitivity to antiviral agents. ED50 values were found to be 3.25-18μM for acyclovir, 5-25μM for vidarabine, 0.49-3.3μM for idoxyuridine and 0.025-0.05μM for bromovinyldeoxyuridine. The wide range of sensitivity to acyclovir lead to a recommendation that the therapeutic dosage used by increased from 5 mg/kg/dose to 10 mg/kg/dose to produce adequate levels in vitro. (D72154/87)

University of Southampton
Larkin, Margot
430f26f6-3c95-4c3e-949a-7cf3e34b21d8
Larkin, Margot
430f26f6-3c95-4c3e-949a-7cf3e34b21d8

Larkin, Margot (1986) Antiviral mechanisms in varicella-zoster virus infections. University of Southampton, Doctoral Thesis.

Record type: Thesis (Doctoral)

Abstract

Six varicella-zoster virus (VZV)-infected cell surface proteins, M{}r 170K, 105K, 93K, 81K, 53K and 45K, were identified following extrinsic radiolabelling of the cell surface, immunoprecipitation of detergent-solubilized extract of the same cell surface and fractionation of the immunoprecipitates using SDS-PAGE. All six were shown to be glycosylated by their affinity for Ricin communis agglutinin 1 lectin. The glycoprotein with M{}r 170K in non-reduced PAGE was shown to be a disulphide bond-linked protein as under reducing conditions it was cleaved to a subunit, M{}r 63K. The human serum IgG response to these glycoproteins during various clinical circumstances was investigated. Antibodies reactive with these glycoproteins could not be detected in acute sera from the chickenpox patients and in the majority of acute shingles cases. Antibodies reactive with glycoproteins with M{}r 170K, 105K, 53K and 45K were identified in post-varicella sera, whilst during zoster convalescence antibodies to all six were prominent. Antibodies to the disulphide bond-linked glycoprotein persisted for many years following both the primary disease and its reactivation. Disseminated zoster was associated with significantly low levels of antibodies to these surface glycoproteins. Virological studies were carried out in 28 non-immunocompromised patients with herpes zoster who received treatment with the antiviral acyclovir (5 mg/kg) or placebo intravenously three times daily for five days. Mean duration of virus shedding was not significantly different in the two groups and all patients developed high titres of IgG antibodies to varicella-zoster virus, IgM and IgA responses were also detected. Interferon levels in sequential vesicle fluids reached a peak significantly sooner (p< 0.025) and at a lower level in eight treated patients compared with eight given placebo. Twenty-five VZV isolates from the zoster patients were tested for sensitivity to antiviral agents. ED50 values were found to be 3.25-18μM for acyclovir, 5-25μM for vidarabine, 0.49-3.3μM for idoxyuridine and 0.025-0.05μM for bromovinyldeoxyuridine. The wide range of sensitivity to acyclovir lead to a recommendation that the therapeutic dosage used by increased from 5 mg/kg/dose to 10 mg/kg/dose to produce adequate levels in vitro. (D72154/87)

This record has no associated files available for download.

More information

Published date: 1986

Identifiers

Local EPrints ID: 460715
URI: http://eprints.soton.ac.uk/id/eprint/460715
PURE UUID: 41e38ce8-ca00-4ec0-acc7-6ec440b577fa

Catalogue record

Date deposited: 04 Jul 2022 18:28
Last modified: 22 Feb 2023 18:54

Export record

Contributors

Author: Margot Larkin

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×